EHA 2017 | Building genetic assessments into how we determine prognosis of ALL

Name: Building genetic assessments into how we determine prognosis of ALL
Uploaded: 2017-06-24T09:54:50.000Z
Duration: 49 s
Description: David Marks, MD, PhD, from the University Hospitals Bristol NHS Foundation Trust, Bristol, UK, talks to us about the need to add genetic assessments into determining the prognosis of acute lymphoblastic leukemia (ALL) patients. This was recorded at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.

David Marks • 24 Jun 2017

EHA 2017

Acute Lymphoblastic Leukemia

David Marks, MD, PhD, from the University Hospitals Bristol NHS Foundation Trust, Bristol, UK, talks to us about the need to add genetic assessments into determining the prognosis of acute lymphoblastic leukemia (ALL) patients. This was recorded at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.